Clinical Trial: NCT04233346
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Otsuka Beijing Research Institute |
| Information Provided By: | Otsuka Beijing Research Institute |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
Official Title
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Conditions
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Intervention / Treatment
- Drug: Ponatinib 30mg OD
- Drug: Ponatinib 45mg OD
Other Study ID Numbers
- 297-403-00003
Start Date (Actual)
2020-07-09
Primary Completion Date (Actual)
2022-07-22
Study Completion Date (Actual)
2026-09-08
Enrollment (Actual)
93
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Otsuka Beijing Research Institute |
| Information Provided By: | Otsuka Beijing Research Institute |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
Official Title
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Conditions
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Intervention / Treatment
- Drug: Ponatinib 30mg OD
- Drug: Ponatinib 45mg OD
Other Study ID Numbers
- 297-403-00003
Start Date (Actual)
2020-07-09
Primary Completion Date (Actual)
2022-07-22
Study Completion Date (Actual)
2026-09-08
Enrollment (Actual)
93
Study Type
Interventional
Phase
Phase 2